Adbry Disease Interactions
There are 3 disease interactions with Adbry (tralokinumab).
Tralokinumab (applies to Adbry) live vaccines
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vaccination
Tralokinumab may alter patient immunity and increase risk of infection after administration of live vaccines. Before starting this drug, complete all age-appropriate vaccinations according to current guidelines. Do not use live vaccines in patients treated tralokinumab.
References (1)
- (2022) "Product Information. Adbry (tralokinumab)." Leo Pharma Inc
Tralokinumab (applies to Adbry) parasitic infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Tralokinumab may influence the immune response against helminth infections by inhibiting interleukin 13 (IL-13) signaling. Patients with preexisting helminth infections should be treated before initiating treatment with this drug. If patients become infected while already in treatment and do not respond to antihelminth treatment, discontinue this drug until infection resolves.
References (1)
- (2022) "Product Information. Adbry (tralokinumab)." Leo Pharma Inc
Tralokinumab (applies to Adbry) visual disturbances
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance
Conjunctivitis and keratitis occurred more frequently in patients with atopic dermatitis who received tralokinmab, being conjunctivitis the most frequently reported eye disorder. Patients should report new onset or worsening of any existing eye symptoms to their healthcare provider.
References (1)
- (2022) "Product Information. Adbry (tralokinumab)." Leo Pharma Inc
Switch to consumer interaction data
Adbry drug interactions
There are 25 drug interactions with Adbry (tralokinumab).
Report options
More about Adbry (tralokinumab)
- Adbry consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opzelura
Opzelura is used to treat atopic dermatitis (eczema) and nonsegmental vitiligo. It is a topical ...
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Cibinqo
Cibinqo (abrocitinib) tablets are used for the treatment of moderate to severe eczema (atopic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Temovate
Temovate is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen ...
Lidex
Lidex is used for atopic dermatitis, dermatitis, eczema, psoriasis
Clobex
Clobex is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Olux
Olux is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Lidex-E
Lidex-E is used for atopic dermatitis, dermatitis, eczema, psoriasis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
